Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline
Authors:
- Michael J. PontecorvoMPMichael J. Pontecorvo
- Stephen P. SallowaySSStephen P. Salloway
- P. Murali DoraiswamyPDP. Murali Doraiswamy
- Adam S. FleisherAFAdam S. Fleisher
- Carl H. SadowskyCSCarl H. Sadowsky
- Anil K. NairANAnil K. Nair
- Andrew SiderowfASAndrew Siderowf
- Ming LuMLMing Lu
- Anupa K. AroraAAAnupa K. Arora
- Abigail AgbulosAAAbigail Agbulos
- Matthew L. FlitterMFMatthew L. Flitter
- 1 January 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 27 (1) , 4-15
Abstract
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to participate at 19 clinical sites. The site physician provided a provisional diagnosis, an estimate of their diagnostic confidence, and their plan for diagnostic evaluation and management both before and after receiving the results from amyloid imaging with florbetapir F18. Analyses compared the frequency of AD and non-AD diagnoses, plans for ancillary testing, and intended patient management before and after florbetapir imaging. A total of 229 patients participated in the trial (113 amyloid positive, 116 amyloid negative). After receiving the results of the florbetapir scan, diagnosis changed in 125/229, or 54.6% [95% confidence intervals (CI), 48.1%-60.9%], of cases, and diagnostic confidence increased by an average of 21.6% (95% CI, 18.3%-24.8%). A total of 199/229 or 86.9% (95% CI, 81.9%-90.7%) of cases had at least 1 change in their management plan. Intended cholinesterase inhibitor or memantine treatment increased by 17.7% (95% CI, 11.8%-25.8%) of all cases with positive scans and decreased by 23.3% (95% CI, 16.5%-31.8%) of all those with negative scans. Among subjects who had not yet undergone a completed work up, planned brain structural imaging (computed tomographic/magnetic resonance imaging) decreased by 24.4% (95% CI, 17.5%-32.8%) and planned neuropsychological testing decreased by 32.8% (95% CI, 25.0%-41.6%). In summary, amyloid imaging results altered physician's diagnostic thinking, intended testing, and management of patients undergoing evaluation for cognitive decline.Keywords
This publication has 36 references indexed in Scilit:
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Clinical Criteria for the Diagnosis of Alzheimer Disease: Still Good After All These YearsThe American Journal of Geriatric Psychiatry, 2008
- Diagnosing cognitive impairment and dementia in primary health care - a more active approach is neededAge and Ageing, 2003
- Practice parameter: Diagnosis of dementia (an evidence-based review)Neurology, 2001
- Identifying Dementia in the Primary Care PracticeInternational Psychogeriatrics, 2000
- Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case SeriesJournal of the American Geriatrics Society, 1999
- Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's DiseaseNew England Journal of Medicine, 1998
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984